Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Resuming warfarin after GI bleeding leads to better outcomes.

Slomski A.

JAMA. 2014 Jan 22-29;311(4):349. doi: 10.1001/jama.2014.61. No abstract available.

PMID:
24449302
2.

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.

Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND.

BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.

3.

Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation.

Qureshi W, Mittal C, Patsias I, Garikapati K, Kuchipudi A, Cheema G, Elbatta M, Alirhayim Z, Khalid F.

Am J Cardiol. 2014 Feb 15;113(4):662-8. doi: 10.1016/j.amjcard.2013.10.044. Erratum in: Am J Cardiol. 2015 Jul 1;116(1):166.

PMID:
24355310
4.

Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.

Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, Becker RC, Singer DE, Halperin JL, Hankey GJ, Berkowitz SD, Fox KA, Patel MR.

J Am Coll Cardiol. 2015 Dec 1;66(21):2271-81. doi: 10.1016/j.jacc.2015.09.024.

5.

Effective antidotes for new anticoagulants.

Lythgoe M.

BMJ. 2015 May 26;350:h2775. doi: 10.1136/bmj.h2775. No abstract available.

PMID:
26014356
6.

Safety of new oral anticoagulants.

Vaughan Sarrazin MS, Rose A.

BMJ. 2015 Apr 24;350:h1679. doi: 10.1136/bmj.h1679. No abstract available.

PMID:
25911527
7.

Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.

Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB.

J Am Coll Cardiol. 2014 May 27;63(20):2141-7. doi: 10.1016/j.jacc.2014.02.549.

8.

Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients.

Lane DA, Lip GY.

Thromb Haemost. 2009 May;101(5):802-5. No abstract available. Erratum in: Thromb Haemost.2010 Sep;104(3):653.

PMID:
19404530
9.

Neither dabigatran nor rivaroxaban were linked to increased GI bleeding compared with warfarin.

Koretz RL.

Ann Intern Med. 2015 Sep 15;163(6):JC13. doi: 10.7326/ACPJC-2015-163-6-013. No abstract available.

PMID:
26370028
10.

Heyde syndrome: a common but less recognized complex of aortic stenosis and bleeding intestinal angiodysplasia.

Hokama A, Kishimoto K, Higashiarakawa M, Chinen H, Kinjo F, Fujita J.

South Med J. 2009 Dec;102(12):1279. doi: 10.1097/SMJ.0b013e3181b72a06. No abstract available.

PMID:
20016445
11.

Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.

Buller HR, Halperin J, Hankey GJ, Pillion G, Prins MH, Raskob GE.

J Thromb Haemost. 2014 Jun;12(6):824-30. doi: 10.1111/jth.12546.

12.

Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis.

Chai-Adisaksopha C, Hillis C, Monreal M, Witt DM, Crowther M.

Thromb Haemost. 2015 Oct;114(4):819-25. doi: 10.1160/TH15-01-0063. Review.

PMID:
26018236
13.

[Anticoagulation therapy of atrial fibrillation].

Gjesdal K.

Tidsskr Nor Laegeforen. 2002 Jan 20;122(2):191-2. Norwegian. No abstract available.

14.

Efficacy of new oral anticoagulants in patients with atrial fibrillation previously treated with warfarin: a meta-analysis of randomized controlled trials.

Fauchier L, Clementy N, Saint-Etienne C, Simeon E, Angoulvant D, Bernard-Brunet A.

Int J Cardiol. 2014 Apr 15;173(1):122-4. doi: 10.1016/j.ijcard.2014.02.027. No abstract available.

PMID:
24636544
16.

Restarting anticoagulation after major gastrointestinal bleeding.

Tardy B, Emilie C.

Am J Cardiol. 2014 May 15;113(10):1776. doi: 10.1016/j.amjcard.2014.03.003. No abstract available.

PMID:
24792745
17.

Warfarin therapy for atrial fibrillation in general practice--is bleeding risk underestimated?

Bratland B, Hornnes MB.

Tidsskr Nor Laegeforen. 2014 Jan 28;134(2):175-9. doi: 10.4045/tidsskr.13.0626. English, Norwegian.

18.

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.

Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators..

Circulation. 2013 Jun 4;127(22):2166-76. doi: 10.1161/CIRCULATIONAHA.112.142158.

19.

Anticoagulation in the elderly.

Henderson MC, White RH.

Curr Opin Pulm Med. 2001 Sep;7(5):365-70. Review.

PMID:
11584191
20.

Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.

Circulation. 2015 Jan 13;131(2):157-64. doi: 10.1161/CIRCULATIONAHA.114.012061.

Supplemental Content

Support Center